Iovance Biotherapeutics (IOVA) EBIAT (2016 - 2025)
Historic EBIAT for Iovance Biotherapeutics (IOVA) over the last 13 years, with Q3 2025 value amounting to -$91.3 million.
- Iovance Biotherapeutics' EBIAT fell 923.14% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 300.1%. This contributed to the annual value of -$372.2 million for FY2024, which is 1617.82% up from last year.
- According to the latest figures from Q3 2025, Iovance Biotherapeutics' EBIAT is -$91.3 million, which was down 923.14% from -$111.7 million recorded in Q2 2025.
- In the past 5 years, Iovance Biotherapeutics' EBIAT ranged from a high of -$78.6 million in Q4 2024 and a low of -$116.4 million during Q4 2023
- Moreover, its 3-year median value for EBIAT was -$107.4 million (2023), whereas its average is -$103.2 million.
- Its EBIAT has fluctuated over the past 5 years, first soared by 3247.75% in 2024, then tumbled by 1499.16% in 2025.
- Quarter analysis of 3 years shows Iovance Biotherapeutics' EBIAT stood at -$116.4 million in 2023, then soared by 32.48% to -$78.6 million in 2024, then decreased by 16.12% to -$91.3 million in 2025.
- Its EBIAT was -$91.3 million in Q3 2025, compared to -$111.7 million in Q2 2025 and -$116.2 million in Q1 2025.